45 citations
,
June 2018 in “Frontiers in immunology” MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
March 2024 in “Stem cell research & therapy” Human dental pulp stem cell-conditioned medium, especially from hypoxic conditions, may help treat chemotherapy-induced hair loss and does not increase cancer risk.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” 1 citations
,
January 2023 in “IntechOpen eBooks” Paclitaxel is an effective cancer drug with side effects and potential new uses beyond cancer.
April 2018 in “Journal of Investigative Dermatology” The role of γδT-cells in causing alopecia areata remains unclear.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
2 citations
,
February 1981 in “Journal of the Royal Society of Medicine” A three-year-old girl survived a rare serious infection caused by BCG vaccination, which improved after treatment with a leprosy drug.
Cyproterone slightly inhibited hair growth in castrated mice, while tamoxifen significantly inhibited hair growth in castrated mice but not in normal mice.
1 citations
,
January 2012 in “Türk jinekoloji ve obstetrik derneði dergisi/Türk Jinekoloji ve Obstetrik Derneği dergisi” Most patients experienced significant but reversible hair loss during treatment.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
54 citations
,
May 2019 in “Multiple Sclerosis and Related Disorders” Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
53 citations
,
August 2014 in “Cochrane library” Methotrexate is not proven effective for inducing remission in ulcerative colitis.
24 citations
,
November 2013 in “Trends in pharmacological sciences” Increasing ABC transporters in hair follicles may prevent chemotherapy-induced hair loss.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
September 2024 in “World Journal of Clinical Oncology” Chemotherapy with docetaxel and cisplatin can cause severe low potassium, requiring careful monitoring and treatment.
155 citations
,
August 1991 in “Journal of The American Academy of Dermatology” Methotrexate treats various disorders by inhibiting DNA synthesis, but careful monitoring is needed to avoid toxicity and manage side effects.
1 citations
,
April 2006 in “International Journal of Oncology” Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
February 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors may help treat alopecia areata by reversing hair loss.
April 2023 in “Dermatology practical & conceptual” Tacrolimus solution is effective and well-tolerated for treating inflammatory scalp conditions.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
5 citations
,
June 2005 in “Journal of Clinical Oncology” PPX causes much less hair loss than traditional taxanes.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
March 2016 in “Journal of evolution of medical and dental sciences” Combining OMP with cyclosporine can effectively treat severe alopecia areata in children.